Everhart Financial Group Inc. Cuts Stock Position in SELLAS Life Sciences Group, Inc. $SLS

Everhart Financial Group Inc. lessened its stake in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 21.0% in the second quarter, Holdings Channel reports. The institutional investor owned 288,018 shares of the company’s stock after selling 76,379 shares during the period. Everhart Financial Group Inc.’s holdings in SELLAS Life Sciences Group were worth $4,251,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Larson Financial Group LLC bought a new stake in SELLAS Life Sciences Group in the fourth quarter worth $26,000. California State Teachers Retirement System grew its stake in shares of SELLAS Life Sciences Group by 22.4% in the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after acquiring an additional 1,709 shares during the last quarter. Beacon Pointe Advisors LLC bought a new position in shares of SELLAS Life Sciences Group during the fourth quarter valued at $38,000. Concurrent Investment Advisors LLC bought a new position in shares of SELLAS Life Sciences Group during the fourth quarter valued at $38,000. Finally, Money Concepts Capital Corp purchased a new position in shares of SELLAS Life Sciences Group in the 4th quarter worth about $40,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Performance

SELLAS Life Sciences Group stock opened at $12.01 on Friday. The stock has a market cap of $2.36 billion, a PE ratio of -52.22 and a beta of 2.48. SELLAS Life Sciences Group, Inc. has a one year low of $1.39 and a one year high of $15.88. The stock has a fifty day moving average of $10.92 and a 200 day moving average of $7.13.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, SELLAS Life Sciences Group currently has an average rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.